Navigation Links
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Date:10/16/2009

e days in 4.4% of patients treated with oral allopurinol alone and 6.5% of patients treated with the Elitek/oral allopurinol combination, versus 0% of patients receiving Elitek alone. Clinical TLS occurred in 3% of Elitek-treated patients, 3% of Elitek/oral allopurinol-treated patients, and 4% of oral allopurinol-treated patients.

Hypersensitivity reactions occurred in 4.3% of patients treated with Elitek alone and 1.1% of patients treated with the Elitek/oral allopurinol combination. Hypersensitivity reactions included arthralgia, injection site irritation, peripheral edema, and rash. The most common Grade 3/4 related adverse reactions regardless of relationship to study drug were sepsis (5.4% / 6.5% / 4.4%), hypophosphatemia (4.3% / 6.5% / 6.6%), anxiety (3.3% / 0% / 0%), abdominal pain (3.3% / 4.3% / 2.2%), hyperbilirubinemia (3.3% / 2.2% / 4.4%) and increased alanine aminotransferase (3.3% / 4.3% / 2.2%) in the Elitek, Elitek/oral allopurinol and oral allopurinol arms, respectively. Of note, all patients were receiving anti-cancer chemotherapy and/or biologic anti-cancer agents for their primary disease. The following serious adverse reactions occurred with a difference in incidence of greater than or equal to 2% in patients receiving Elitek compared to patients receiving oral allopurinol: pulmonary hemorrhage, respiratory failure, supraventricular arrhythmias, ischemic coronary artery disorders, and abdominal and gastrointestinal infections.

Based on the results of the above study, Elitek is now indicated at a daily dose of 0.20 mg/kg intravenously for up to 5 days for the initial management of plasma uric acid levels in adults with leukemia, lymphoma and solid tumors receiving anti-cancer therapy expected to result in tumor lysis syndrome and subsequent elevation of plasma uric acid.

About Elitek®

A recombinant urate oxidase enzyme, Elitek is the first recombinant uricolytic agent approved in the U.S. t
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
2. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
3. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
4. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
5. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
6. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
7. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
8. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
9. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
10. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
11. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oct. 31, 2014  Australian biopharmaceutical company Specialised Therapeutics ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be ... with metastatic pancreatic cancer from 1 November. ... is the 5 th most common cause of ... cancer deaths, with the lowest 5-year survival of all ...
(Date:10/31/2014)... -- Investor-Edge has initiated coverage on the ... Isis Pharmaceuticals Inc. (NASDAQ: ISIS ), Halozyme ... Inc. (NASDAQ: ACAD ), and Synta Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,566.14, up 0.37%, the Dow Jones Industrial Average ...
(Date:10/31/2014)... Australia and BARCELONA , October ... Ltd (Multigate) was found to infringe two Australian patents of ... for sale in Australia safety IV ... 17.10.14 in Federal Court of Australia ... http://www.austlii.edu.au/au/cases/cth/FCA/2014/1110.html . In the detailed judgment, ...
Breaking Medicine Technology:Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2
... Beshear announced yesterday that most of Kentucky,s Medicaid program ... $375 million. In modernizing the state,s Medicaid pharmacy benefits, ... pharmacy benefit managers (PBMs) to lower prescription drug costs, ... "Governor Beshear has done the right thing ...
... 8, 2011 Stryker Joint Preservation, a business unit ... American Orthopaedic Society for Sports Medicine meeting that it ... to distribute Stryker,s RegenKit-THT, a one-step system designed for ... (A-PRP) from a small sample of blood at the ...
Cached Medicine Technology:Modernizing Medicaid Rx with 'Innovative' PBM Tools Will Help Kentucky Save $375 Million 2Stryker Announces Exclusive Collaboration With RegenLab 2
(Date:10/31/2014)... TheHardwareCity.com is the place to purchase home ... space heaters are available at the online store. Now, ... 1500w portable electric space heater. , The space heater ... an energy efficient way to heat a small space ... produce 1500 Watts, ensuring a quick warm up period. ...
(Date:10/31/2014)... Prevention Research Center for Healthy Neighborhoods (PRCHN) at ... a key player in nearly $13.32 million in ... Northeast Ohio. , The Centers for Disease Control ... $4.35 million over five years. The funds will ... and disseminating individual, environmental, and policy interventions that ...
(Date:10/31/2014)... Thousand Oaks, CA (PRWEB) October 31, 2014 ... flat tummy also has amazing health effects for ... were created by a Doctor of Science and ... discovered through his dedication to pelvic floor reeducation ... incidence of urinary incontinence, Diastasis Recti, Prolepses, etc. ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... of four older Americans say that either they or ... treatment, according to the latest issue of The Gerontological ... ( PP&AR ), which goes on to show ... fail to honor patients, end-of-life health care wishes. , ... Issues and Options ," features 12 articles that present ...
Breaking Medicine News(10 mins):Health News:Big Heat 1500w Electric Space Heater Now Available at TheHardwareCity.com 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2
... potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV ... concludes a new study published online February 15 in the ... found that the rate of new infections preventable by vaccination ... any age typically do not progress to cervical intraepithelial neoplasia ...
... skull bone appear to be a durable treatment option that ... according to a report in the February issue of ... of the JAMA/Archives journals. , Single-sided deafness, also ... percent and 3 percent of children, according to background information ...
... and lungs suffer, study finds , MONDAY, Feb. 15 (HealthDay ... pipes or cigars instead of cigarettes are kidding themselves, a ... means is deleterious," said Dr. R. Graham Barr, assistant professor ... lead author of a report in the Feb. 16 issue ...
... further problems, experts say, , MONDAY, Feb. 15 (HealthDay News) ... are likely to have another stroke soon after the initial ... according to a new study by researchers from the Medical ... importance of recognizing that anyone who has had a stroke ...
... As more people undergo bariatric procedures, use of revisions ... News) -- Repeat weight-loss surgery carries a higher risk ... has found. , The surgical treatment, known as bariatric ... loss in severely obese people. Rates of repeat bariatric ...
... Small study shows patients with ocular type benefit from ... toxin type A (Botox), the drug that can temporarily ... migraines, a small study suggests. , Specifically, Botox may ... as crushing or eye-popping, otherwise known as ocular migraines. ...
Cached Medicine News:Health News:News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low 2Health News:Bone-anchored hearing aids help youth with single-sided deafness 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 3Health News:After a Stroke, High Risk for a Recurrence 2Health News:After a Stroke, High Risk for a Recurrence 3Health News:Repeated Weight-Loss Surgery Carries Added Risks 2Health News: Botox May Prevent Some Migraines 2Health News: Botox May Prevent Some Migraines 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: